Journal of Clinical Immunology

, Volume 34, Issue 8, pp 1015–1017 | Cite as

Intravenous and Subcutaneous Immunoglobulin Replacement: A Two-Way Road. Optimizing Healthcare Quality in Patients with Primary Immunodeficiencies

  • Pere Soler-Palacín
  • Ingrid Gasó-Gago
  • Aurora Fernández-Polo
  • Andrea Martín-Nalda
  • María Oliveras
  • Julio Martinez-Cutillas
  • Concepció Figueras
Brief Communication



To evaluate the alternate use of subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencies (PID) in a third-level Pediatric University Hospital.


Retrospective study of all patients receiving SCIG from 2006 to 2012. Data collected included demographics, date SCIG was started, date of switch to IVIG and reasons, administration tolerance, and related adverse events. Effectiveness was defined as the lack of severe infections.


Twenty-three patients (15 male, 8 female) with PID were studied. SCIG was initiated at a median age of 14.2 years (8.4 months-25.7 years) and median duration on SCIG treatment was 41 months (4-68). Nine patients (39.1%) temporarily switched from SCIG to IVIG for the following reasons: vacation (8), administration issues (1), and transient need for immunomodulatory therapy (1). A mean of 5.2 IVIG infusions/patient (SD=2.86) was administered while on SCIG. IVIG-related adverse events were documented in 3 patients with 6 infusions. Eight (34.8%) patients definitively discontinued SCIG use for the following reasons: convenience (5), adverse effects (1), coagulopathy (1), and autoimmune thrombocytopenia (1). There were no severe infections requiring hospital admission in any patient during the study period.


Alternating SCIG and IVIG use in patients with PID was associated with considerable advantages in terms of convenience for the patients and their caregivers, while maintaining the effectiveness and safety of this therapy. Healthcare units treating these patients should show flexibility with this dual therapy in order to optimize patients’ quality of life.


Intravenous immunoglobulins primary immunodeficiency quality of life subcutaneous immunoglobulins 


  1. 1.
    Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol. 2002;104:237–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158 Suppl 1:14.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    European Society for Immunodeficiencies. PID Care in Development. [Consultado el 8 de Abril de 2014]. Available in
  6. 6.
    European Society for Immunodeficiencies. Additional Statistics. [Consultado el 30 de noviembre de 2013]. Available in
  7. 7.
    Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol. 2005;1(3):120–30.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Melamed I, McDonald A, Neff A, Beck A. An analysis of safety and tolerability data on 10 %, 16 %, and 20 % formulations of subcutaneous immunoglobulin (IGSC). J Allergy Clin Immunol. 2011;127:AB16.CrossRefGoogle Scholar
  10. 10.
    Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J. 1997;16:696–707.PubMedCrossRefGoogle Scholar
  12. 12.
    Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73(12):1307–19.PubMedCrossRefGoogle Scholar
  14. 14.
    Shapiro RS. Why I, use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013;33 Suppl 2:S95–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Torgerson TR. Overview of routes of IgG administration. J Clin Immunol. 2013;33 Suppl 2:S87–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238–45.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Torgerson T, Bonagura V, Shapiro R. Clinical ambiguities—ongoing questions. J Clin Immunol. 2013;33 Suppl 2:S99–103.PubMedCrossRefGoogle Scholar
  24. 24.
    Torgerson T. Comparing routes of IgG administration for primary immunodeficiency disorders. Clin Immunol. 2013;33 Suppl 2:S85–6.CrossRefGoogle Scholar
  25. 25.
    Maroto Hernando M, Soler-Palacín P, Martin-Nalda N, Oliveras Arenas M, Español Boren T, Figueras NC. Subcutaneous gammaglobulin in common variable immunodeficiency: first experience in Spain. An Pediatr. 2009;70:111–9.CrossRefGoogle Scholar
  26. 26.
    Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10 % caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Pere Soler-Palacín
    • 1
  • Ingrid Gasó-Gago
    • 2
  • Aurora Fernández-Polo
    • 2
  • Andrea Martín-Nalda
    • 1
  • María Oliveras
    • 2
  • Julio Martinez-Cutillas
    • 2
  • Concepció Figueras
    • 1
  1. 1.Pediatric Infectious Diseases and Immunodeficiencies UnitHospital Universitari Vall d’Hebron. Institut de Recerca Vall d’Hebron. Universitat Autònoma de BarcelonaBarcelonaSpain
  2. 2.Pharmacy DepartmentVall d’Hebron HospitalBarcelonaSpain

Personalised recommendations